Program
Insulin Glargine
Also written as “insulin glargine”, “Insulin glargine” and “INSULIN GLARGINE”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Hyperglycemia · Glucose Intolerance, led by 9 companies.
Drug pageInsulin Glargine: every studyMany companies study it; this page follows only the 184 they lead. All 294 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 1241 open or running | phase 4since Sep 9, 2005 | Sep 30, 2002 | none ahead |
| Novo Nordiskits history only | 280 open or running | phase 4since Sep 12, 2005 | Oct 29, 2004 | none ahead |
| Eli Lillyits history only | 250 open or running | phase 4since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Diabetes Care Centerits history only | 20 open or running | no phasesince Apr 3, 2007 | Apr 3, 2007 | none ahead |
| Biodelits history only | 10 open or running | phase 2since Oct 21, 2009 | Oct 21, 2009 | none ahead |
| Geropharmits history only | 10 open or running | no phasesince Sep 23, 2019 | Sep 23, 2019 | none ahead |
| ikfe-CROits history only | 10 open or running | phase 4since Dec 5, 2011 | Dec 5, 2011 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 1since Sep 3, 2009 | Sep 3, 2009 | none ahead |
| Wockhardtits history only | 10 open or running | phase 1since May 12, 2011 | May 12, 2011 | none ahead |
Also a collaborator on its studies: PPD DEVELOPMENT, LP, Alkermes and Boehringer Ingelheim.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Sep 14, 2012.
- Dec 5, 2018Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT03767543 · 265 enrolled · Canada
- Jan 7, 20192 phase 3 studies in Diabetes Mellitus, Type 2Sanofi · NCT03798080, NCT03798054
- Aug 29, 2019Phase 4 study in Diabetes Mellitus, Type 1Sanofi · NCT04075513 · 343 enrolled · United States, Brazil, Germany and more
- Sep 23, 2019Geropharm’s first study: no phase study in Clamp StudyNew to GeropharmGeropharm · NCT04101383 · 42 enrolled · Russian Federation
- Nov 5, 2019Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT04153981 · 304 enrolled · India
- Jul 10, 2020No phase study in Diabetes Mellitus, Type 1Eli Lilly · NCT04484779 · 67 enrolled · United States
- Apr 27, 2021Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT04864977 · United States
- Jul 19, 2021Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT04980027 · 228 enrolled · India
- Oct 29, 2021Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT05114590 · 124 enrolled · United States
- Jun 7, 2022Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT05413369 · 582 enrolled · China
- Jul 14, 2022Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT05462756 · 730 enrolled · United States, Argentina, Germany and more
- Sep 7, 2022Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT05552859 · 62 enrolled · United States, Czechia, Hungary and more
- Mar 26, 2024Phase 3 study in Diabetes Mellitus, Type 2Novo Nordisk · NCT06340854 · 412 enrolled · United States, Bulgaria, Germany and more
- Oct 31, 2024Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT06671587 · 678 planned · China
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
The newest 60 of 184 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06671587Diabetes Mellitus, Type 2 · China | 4 | Recruiting | Sanofi | Sep 18, 2026 | 678 |
| NCT06340854Diabetes Mellitus, Type 2 · United States, Bulgaria, Germany and more | 3 | Completed | Novo Nordisk | May 8, 2025 | 412 |
| NCT05552859Diabetes Mellitus, Type 2 · United States, Czechia, Hungary and more | 4 | Terminated | Sanofi | Jul 28, 2023 | 62 |
| NCT05462756Diabetes Mellitus, Type 2 · United States, Argentina, Germany and more | 3 | Completed | Eli Lilly | Feb 27, 2024 | 730 |
| NCT05413369Diabetes Mellitus, Type 2 · China | 3 | Completed | Sanofi | Oct 20, 2023 | 582 |
| NCT05114590Diabetes Mellitus, Type 2 · United States | 4 | Completed | Sanofi | Mar 28, 2023 | 124 |
| NCT04980027Diabetes Mellitus, Type 2 · India | 4 | Completed | Sanofi | Dec 23, 2022 | 228 |
| NCT04864977Diabetes Mellitus, Type 2 · United States | 4 | Withdrawn | Eli Lilly | Jun 6, 2022 | 0 |
| NCT04484779Diabetes Mellitus, Type 1 · United States | – | Completed | Eli Lilly | Dec 22, 2020 | 67 |
| NCT04153981Diabetes Mellitus, Type 2 · India | 4 | Completed | Eli Lilly | Jul 30, 2021 | 304 |
| NCT04101383Clamp Study · Russian Federation | – | Completed | Geropharm | Feb 16, 2018 | 42 |
| NCT04075513Diabetes Mellitus, Type 1 · United States, Brazil, Germany and more | 4 | Completed | Sanofi | Sep 16, 2021 | 343 |
| NCT03798080Diabetes Mellitus, Type 2 · China | 3 | Completed | Sanofi | Dec 1, 2020 | 426 |
| NCT03798054Diabetes Mellitus, Type 2 · China, Korea, Republic of, Malaysia and more | 3 | Completed | Sanofi | Mar 1, 2021 | 878 |
| NCT03767543Diabetes Mellitus, Type 2 · Canada | 3 | Completed | Sanofi | Oct 23, 2020 | 265 |
| NCT03760991Diabetes Mellitus, Type 2 · Argentina, Colombia, Egypt and more | 4 | Completed | Sanofi | Sep 23, 2020 | 372 |
| NCT03555305Healthy · China | 1 | Completed | Eli Lilly | Nov 4, 2019 | 58 |
| NCT03529123Diabetes Mellitus, Type 2 · India | 3 | Completed | Sanofi | Nov 25, 2019 | 247 |
| NCT03434119Diabetes Mellitus, Type 2 · United States | 3 | Terminated | Sanofi | Jan 7, 2019 | 241 |
| NCT03406000Diabetes Mellitus, Type 1 · Brazil | 4 | Completed | Sanofi | Feb 4, 2019 | 170 |
| NCT03359837Diabetes Mellitus, Type 2 · China | 4 | Completed | Sanofi | Jun 29, 2020 | 384 |
| NCT03338023Diabetes Mellitus, Type 1 · China | 3 | Completed | Eli Lilly | Mar 5, 2020 | 272 |
| NCT03338010Diabetes Mellitus, Type 2 · China | 3 | Completed | Eli Lilly | Mar 18, 2020 | 536 |
| NCT03260868Diabetes Mellitus, Type 1 · United States, Canada | 4 | Terminated | Sanofi | Nov 22, 2018 | 15 |
| NCT02967237Diabetes Mellitus, Type 2 · France | 4 | Completed | Sanofi | Jul 24, 2017 | 136 |
| NCT02967224Diabetes Mellitus, Type 2 · Brazil, France, Germany and more | 4 | Completed | Sanofi | Oct 16, 2017 | 705 |
| NCT02967211Diabetes Mellitus, Type 2 · Brazil, Finland, France and more | 4 | Completed | Sanofi | Oct 20, 2017 | 609 |
| NCT02955953Healthy · Singapore | 1 | Completed | Eli Lilly | Jan 4, 2017 | 127 |
| NCT02855684Diabetes Mellitus, Type 2 · China, Korea, Republic of, Taiwan | 3 | Completed | Sanofi | Aug 6, 2018 | 604 |
| NCT02836704Diabetes Mellitus, Type 2 · China | 4 | Completed | Sanofi | Apr 26, 2018 | 892 |
| NCT02787551Diabetes Mellitus, Type 2 · United States, Canada, Estonia and more | 3 | Completed | Sanofi | May 25, 2018 | 514 |
| NCT02752828Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Sanofi | Mar 12, 2018 | 521 |
| NCT02752412Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Sanofi | Oct 4, 2018 | 513 |
| NCT02749890Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Sanofi | May 2018 | 321 |
| NCT02738151Diabetes Mellitus, Type 2 · United States, Bulgaria, Croatia and more | 4 | Completed | Sanofi | Aug 15, 2017 | 929 |
| NCT02735044Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more | 3 | Completed | Sanofi | May 31, 2018 | 463 |
| NCT02713477Diabetes Mellitus, Type 2 · Japan | 1 | Completed | Sanofi | Jun 2016 | 20 |
| NCT02688933Diabetes Mellitus, Type 1 · United States, Puerto Rico | 4 | Completed | Sanofi | Jun 19, 2017 | 638 |
| NCT02606357Diabetes Mellitus, Type 2 · Jordan | 4 | Completed | Sanofi | Nov 27, 2017 | 242 |
| NCT02545842Diabetes Mellitus, Type 2 · China | 4 | Completed | Sanofi | Apr 20, 2018 | 947 |
| NCT02451137Diabetes Mellitus, Type 2 · United States, Canada | 4 | Completed | Sanofi | Mar 2, 2018 | 3,304 |
| NCT02401243Diabetes Mellitus, Type 2 · Canada | 3 | Completed | Sanofi | Feb 2016 | 253 |
| NCT02320721Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Sanofi | May 2016 | 1,014 |
| NCT02302716Diabetes Mellitus, Type 2 · United States, India, Korea, Republic of and more | 3 | Completed | Eli Lilly | Jul 2016 | 493 |
| NCT02227212Diabetes Mellitus, Type 2 · Germany | 3 | Completed | Sanofi | Nov 2014 | 40 |
| NCT02201199Diabetes Mellitus, Type 1 · Germany | 1 | Completed | Sanofi | Nov 2014 | 36 |
| NCT02132637Diabetes Mellitus, Type 2 · United States, Germany | 3 | Completed | Eli Lilly | Jul 2015 | 68 |
| NCT02058160Diabetes Mellitus, Type 2 · United States, Australia, Canada and more | 3 | Completed | Sanofi | Jul 2015 | 736 |
| NCT02058147Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more | 3 | Completed | Sanofi | Jun 2015 | 1,170 |
| NCT02034513Diabetes Mellitus · United States, Poland, Puerto Rico | 3 | Completed | Novo Nordisk | Jan 11, 2016 | 501 |
| NCT02030600Diabetes Mellitus · United States, Puerto Rico | 3 | Completed | Novo Nordisk | Dec 4, 2015 | 721 |
| NCT02027753Diabetes Mellitus, Type 2 · Korea, Republic of | 4 | Completed | Sanofi | Apr 2015 | 109 |
| NCT01868529Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jun 2008 | 63 |
| NCT01849289Diabetes Mellitus · United States, Brazil, Canada and more | 3 | Completed | Novo Nordisk | May 15, 2014 | 833 |
| NCT01838083Type1 Diabetes · Germany | 1 | Completed | Sanofi | Aug 2013 | 50 |
| NCT01730014Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jul 2013 | 70 |
| NCT01704417Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Mar 2013 | 40 |
| NCT01688635Healthy · Singapore | 1 | Completed | Eli Lilly | Feb 2013 | 91 |
| NCT01689142Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Sanofi | Nov 2013 | 240 |
| NCT01689129Diabetes Mellitus, Type 1 · Japan | 3 | Completed | Sanofi | Oct 2013 | 243 |
How it is read
Names in the registry
- “insulin glargine”, 38 entries
- “Insulin Glargine”, 27 entries
- “Insulin glargine”, 20 entries
- “INSULIN GLARGINE”, 15 entries
- “LY2963016”, 11 entries
Codes read as this program: HOE901.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 124 studies
- Diabetes Mellitus, Type 1, 44 studies
- Diabetes Mellitus, 14 studies
- Hyperglycemia, 1 study
- Glucose Intolerance, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.